SU11248A1
(en)
|
1927-03-29 |
1929-09-30 |
В.С. Григорьев |
Anthracene cleaning method
|
CU22545A1
(en)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
|
US4289872A
(en)
|
1979-04-06 |
1981-09-15 |
Allied Corporation |
Macromolecular highly branched homogeneous compound based on lysine units
|
JPS57206622A
(en)
|
1981-06-10 |
1982-12-18 |
Ajinomoto Co Inc |
Blood substitute
|
US4671958A
(en)
|
1982-03-09 |
1987-06-09 |
Cytogen Corporation |
Antibody conjugates for the delivery of compounds to target sites
|
US4486414A
(en)
|
1983-03-21 |
1984-12-04 |
Arizona Board Of Reagents |
Dolastatins A and B cell growth inhibitory substances
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4753894A
(en)
|
1984-02-08 |
1988-06-28 |
Cetus Corporation |
Monoclonal anti-human breast cancer antibodies
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
US4625014A
(en)
|
1984-07-10 |
1986-11-25 |
Dana-Farber Cancer Institute, Inc. |
Cell-delivery agent
|
US4542225A
(en)
|
1984-08-29 |
1985-09-17 |
Dana-Farber Cancer Institute, Inc. |
Acid-cleavable compound
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
EP0229108B1
(en)
|
1985-06-26 |
1990-12-27 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5229490A
(en)
|
1987-05-06 |
1993-07-20 |
The Rockefeller University |
Multiple antigen peptide system
|
US4816444A
(en)
|
1987-07-10 |
1989-03-28 |
Arizona Board Of Regents, Arizona State University |
Cell growth inhibitory substance
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
US5204244A
(en)
|
1987-10-27 |
1993-04-20 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
US4847325A
(en)
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
GB8824591D0
(en)
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Fractionation process
|
US5076973A
(en)
|
1988-10-24 |
1991-12-31 |
Arizona Board Of Regents |
Synthesis of dolastatin 3
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
ATE135370T1
(en)
|
1988-12-22 |
1996-03-15 |
Kirin Amgen Inc |
CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US4978744A
(en)
|
1989-01-27 |
1990-12-18 |
Arizona Board Of Regents |
Synthesis of dolastatin 10
|
ES2247656T3
(en)
|
1989-04-19 |
2006-03-01 |
Enzon, Inc. |
A PROCESS TO FORM A MODIFIED POLYPEPTIDE THAT INCLUDES A POLYPEPTIDE AND A POLYCHYLENE OXIDE.
|
US5324844A
(en)
|
1989-04-19 |
1994-06-28 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
US4879278A
(en)
|
1989-05-16 |
1989-11-07 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
|
US4986988A
(en)
|
1989-05-18 |
1991-01-22 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
|
EP0400472B1
(en)
|
1989-05-27 |
1996-04-03 |
Sumitomo Pharmaceuticals Company, Limited |
Process for preparing polyethylene glycol derivatives and modified protein.
|
US5138036A
(en)
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
US5312808A
(en)
|
1989-11-22 |
1994-05-17 |
Enzon, Inc. |
Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
US5219564A
(en)
|
1990-07-06 |
1993-06-15 |
Enzon, Inc. |
Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
|
US5492821A
(en)
|
1990-11-14 |
1996-02-20 |
Cargill, Inc. |
Stabilized polyacrylic saccharide protein conjugates
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
CZ282603B6
(en)
|
1991-03-06 |
1997-08-13 |
Merck Patent Gesellschaft Mit Beschränkter Haftun G |
Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
|
WO1992016555A1
(en)
|
1991-03-18 |
1992-10-01 |
Enzon, Inc. |
Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
|
US5595732A
(en)
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
WO1992022653A1
(en)
|
1991-06-14 |
1992-12-23 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5281698A
(en)
|
1991-07-23 |
1994-01-25 |
Cetus Oncology Corporation |
Preparation of an activated polymer ester for protein conjugation
|
ES2136092T3
(en)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
|
IT1260468B
(en)
|
1992-01-29 |
1996-04-09 |
|
METHOD FOR MAINTAINING THE ACTIVITY OF PROTEOLYTIC ENZYMES MODIFIED WITH POLYETHYLENGLYCOL
|
WO1993016177A1
(en)
|
1992-02-11 |
1993-08-19 |
Cell Genesys, Inc. |
Homogenotization of gene-targeting events
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
ATE156158T1
(en)
|
1992-04-14 |
1997-08-15 |
Cornell Res Foundation Inc |
MACROMOLECULES BASED ON DENDRITIC POLYMERS AND METHOD FOR THE PRODUCTION
|
US5869644A
(en)
|
1992-04-15 |
1999-02-09 |
The Johns Hopkins University |
Synthesis of diverse and useful collections of oligonucleotidies
|
ZA933926B
(en)
|
1992-06-17 |
1994-01-03 |
Amgen Inc |
Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
|
WO1994004193A1
(en)
|
1992-08-21 |
1994-03-03 |
Enzon, Inc. |
Novel attachment of polyalkylene oxides to bio-effecting substances
|
US5382657A
(en)
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
NZ250375A
(en)
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
US5298643A
(en)
|
1992-12-22 |
1994-03-29 |
Enzon, Inc. |
Aryl imidate activated polyalkylene oxides
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
AU6029594A
(en)
|
1993-01-15 |
1994-08-15 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
US5349001A
(en)
|
1993-01-19 |
1994-09-20 |
Enzon, Inc. |
Cyclic imide thione activated polyalkylene oxides
|
US5410024A
(en)
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US5321095A
(en)
|
1993-02-02 |
1994-06-14 |
Enzon, Inc. |
Azlactone activated polyalkylene oxides
|
IL104734A0
(en)
|
1993-02-15 |
1993-06-10 |
Univ Bar Ilan |
Bioactive conjugates of cellulose with amino compounds
|
WO1994028024A1
(en)
|
1993-06-01 |
1994-12-08 |
Enzon, Inc. |
Carbohydrate-modified polymer conjugates with erythropoietic activity
|
WO1995000162A1
(en)
|
1993-06-21 |
1995-01-05 |
Enzon, Inc. |
Site specific synthesis of conjugated peptides
|
GB9317618D0
(en)
|
1993-08-24 |
1993-10-06 |
Royal Free Hosp School Med |
Polymer modifications
|
US5919455A
(en)
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5643575A
(en)
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
NZ276943A
(en)
|
1993-11-10 |
1998-02-26 |
Schering Corp Substituted For |
Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
|
US5951974A
(en)
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
US5446090A
(en)
|
1993-11-12 |
1995-08-29 |
Shearwater Polymers, Inc. |
Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
|
GB9401182D0
(en)
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
US5473034A
(en)
|
1994-03-18 |
1995-12-05 |
Hyogo Prefectural Government |
Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
US5629384A
(en)
|
1994-05-17 |
1997-05-13 |
Consiglio Nazionale Delle Ricerche |
Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
|
WO1995033490A1
(en)
|
1994-06-02 |
1995-12-14 |
Enzon, Inc. |
Method of solubilizing substantially water insoluble materials
|
US5730990A
(en)
|
1994-06-24 |
1998-03-24 |
Enzon, Inc. |
Non-antigenic amine derived polymers and polymer conjugates
|
US5504191A
(en)
|
1994-08-01 |
1996-04-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide methyl esters
|
US5521284A
(en)
|
1994-08-01 |
1996-05-28 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides and esters
|
US5530097A
(en)
|
1994-08-01 |
1996-06-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory peptide amides
|
DE69534530T2
(en)
|
1994-08-12 |
2006-07-06 |
Immunomedics, Inc. |
FOR B-CELL LYMPHOMA AND LEUKEMIA SPECIMEN IMMUNOCONJUGATES AND HUMAN ANTIBODIES
|
US5650234A
(en)
|
1994-09-09 |
1997-07-22 |
Surface Engineering Technologies, Division Of Innerdyne, Inc. |
Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
|
US5554725A
(en)
|
1994-09-14 |
1996-09-10 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Synthesis of dolastatin 15
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
EP1076092A3
(en)
|
1994-10-21 |
2001-03-28 |
Innogenetics N.V. |
Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents
|
CA2204726A1
(en)
|
1994-11-09 |
1996-12-27 |
Robin E. Offord |
Functionalized polymers for site-specific attachment
|
US5599902A
(en)
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
US5738846A
(en)
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
US5756662A
(en)
|
1995-03-14 |
1998-05-26 |
Corixa Corporation |
Compounds and methods for the detection of T. cruzi infection
|
EP0821671B1
(en)
|
1995-04-20 |
2000-12-27 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
|
AU5893696A
(en)
|
1995-06-07 |
1996-12-30 |
Novo Nordisk A/S |
Modification of polypeptides
|
CA2222231A1
(en)
|
1995-06-07 |
1996-12-19 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US5672662A
(en)
|
1995-07-07 |
1997-09-30 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
DK0780386T3
(en)
|
1995-12-20 |
2003-02-03 |
Hoffmann La Roche |
matrix metalloprotease
|
CN103275221B
(en)
|
1996-02-09 |
2016-08-17 |
艾伯维生物技术有限公司 |
People's antibody in conjunction with human TNF alpha
|
KR19990082463A
(en)
|
1996-02-13 |
1999-11-25 |
돈 리사 로얄 |
Quinazolin derivatives as vascular endothelial growth factor inhibitors
|
CN1116286C
(en)
|
1996-03-05 |
2003-07-30 |
曾尼卡有限公司 |
4-anilinoquinazoline derivatives
|
US5747639A
(en)
|
1996-03-06 |
1998-05-05 |
Amgen Boulder Inc. |
Use of hydrophobic interaction chromatography to purify polyethylene glycols
|
TW517067B
(en)
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
TR199900066T2
(en)
|
1996-07-18 |
1999-04-21 |
Pfizer Inc. |
Matrix metalloprotateazlar�n phosphinate bazl� inhibit�rleri
|
SI0964702T1
(en)
|
1996-08-02 |
2007-02-28 |
Ortho Mcneil Pharm Inc |
Polypeptides having a single covalently bound n-terminal water-soluble polymer
|
US5980948A
(en)
|
1996-08-16 |
1999-11-09 |
Osteotech, Inc. |
Polyetherester copolymers as drug delivery matrices
|
PL331895A1
(en)
|
1996-08-23 |
1999-08-16 |
Pfizer |
Arylosulphonylamino derivatives of hydroxamic acid
|
US6130237A
(en)
|
1996-09-12 |
2000-10-10 |
Cancer Research Campaign Technology Limited |
Condensed N-aclyindoles as antitumor agents
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US6214966B1
(en)
|
1996-09-26 |
2001-04-10 |
Shearwater Corporation |
Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
|
US6077864A
(en)
|
1997-01-06 |
2000-06-20 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
JP2001508783A
(en)
|
1997-01-29 |
2001-07-03 |
ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー |
PEGylation method
|
BR9807815A
(en)
|
1997-02-03 |
2000-03-08 |
Pfizer Prod Inc |
Arylsulfonylamino-hydroxamic acid derivatives
|
WO1998034915A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
HUP0000657A3
(en)
|
1997-02-11 |
2000-10-30 |
Pfizer |
N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them
|
WO1998035985A1
(en)
|
1997-02-12 |
1998-08-20 |
The Regents Of The University Of Michigan |
Protein markers for lung cancer and use thereof
|
DE69832158T2
(en)
|
1997-02-25 |
2006-08-10 |
Arizona Board Of Regents, Tempe |
ISOLATION AND STRUCTURAL EXPLANATION OF CRYOSTATIC LINEARS AND CYCLO DEPSIPEPTIDES DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18
|
EP0979102A4
(en)
|
1997-04-30 |
2005-11-23 |
Enzon Inc |
Polyalkylene oxide-modified single chain polypeptides
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US5990237A
(en)
|
1997-05-21 |
1999-11-23 |
Shearwater Polymers, Inc. |
Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
|
HUP0001153A3
(en)
|
1997-06-06 |
2000-12-28 |
Kyowa Hakko Kogyo Kk |
Chemically modified polypeptides, process for producing thereof, pharmaceutical compositions comprising these polypeptides and their use
|
ES2297889T3
(en)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
DERIVATIVES OF HORMONE OF GROWTH AND RELATED PROTEINS.
|
EA002490B1
(en)
|
1997-08-08 |
2002-06-27 |
Пфайзер Продактс Инк. |
Aryloxyarylsulfonylamino hydroxamic acid derivatives
|
WO1999016318A1
(en)
|
1997-09-26 |
1999-04-08 |
Uab Research Foundation |
Reduced antigenic cells and uses therefor
|
US6004573A
(en)
|
1997-10-03 |
1999-12-21 |
Macromed, Inc. |
Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
|
US6201072B1
(en)
|
1997-10-03 |
2001-03-13 |
Macromed, Inc. |
Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
|
DE19748489A1
(en)
|
1997-11-03 |
1999-05-06 |
Roche Diagnostics Gmbh |
Polyethylene glycol-derivatized biomolecules and their use in heterogeneous detection methods
|
US6448369B1
(en)
|
1997-11-06 |
2002-09-10 |
Shearwater Corporation |
Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
US5985263A
(en)
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US5981709A
(en)
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
US6423685B1
(en)
|
1998-03-05 |
2002-07-23 |
Chiron Corporation |
Method for increasing the serum half-life of a biologically active molecule
|
DK1061954T3
(en)
|
1998-03-12 |
2004-10-18 |
Nektar Therapeutics Al Corp |
Polyethylene glycol derivatives with proximal reactive groups
|
JP4462654B2
(en)
|
1998-03-26 |
2010-05-12 |
ソニー株式会社 |
Video material selection device and video material selection method
|
PA8469501A1
(en)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
|
PA8469401A1
(en)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
BICYCLE DERIVATIVES OF HYDROXAMIC ACID
|
EP0953639A1
(en)
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
WO1999057134A1
(en)
|
1998-05-06 |
1999-11-11 |
Genentech, Inc. |
Protein purification by ion exchange chromatography
|
CN1330675A
(en)
|
1998-08-28 |
2002-01-09 |
格莱风科学公司 |
Polyamide chains of precise length, methods to manufacture them and their conjugates with protein
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6114361A
(en)
|
1998-11-05 |
2000-09-05 |
Pfizer Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
WO2000034337A1
(en)
|
1998-12-10 |
2000-06-15 |
Tsukuba Research Laboratory, Toagosei Co., Ltd. |
Humanized monoclonal antibodies against vascular endothelial cell growth factor
|
US6451346B1
(en)
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
JP4805432B2
(en)
|
1998-12-28 |
2011-11-02 |
ランクセス・ドイチュランド・ゲーエムベーハー |
Chemicals for admixing adhesives used in manufacturing wood materials or wood composite materials
|
US6281211B1
(en)
|
1999-02-04 |
2001-08-28 |
Euro-Celtique S.A. |
Substituted semicarbazides and the use thereof
|
KR100838617B1
(en)
|
1999-02-10 |
2008-06-16 |
아스트라제네카 아베 |
Quinazoline derivatives as angiogenesis inhibitors
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
EP1171006B1
(en)
|
1999-04-16 |
2006-03-29 |
Wm. MARSH RICE UNIVERSITY |
Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol)
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US6924359B1
(en)
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
US6323315B1
(en)
|
1999-09-10 |
2001-11-27 |
Basf Aktiengesellschaft |
Dolastatin peptides
|
PT1244647E
(en)
|
1999-11-05 |
2006-10-31 |
Astrazeneca Ab |
QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS
|
US6348558B1
(en)
|
1999-12-10 |
2002-02-19 |
Shearwater Corporation |
Hydrolytically degradable polymers and hydrogels made therefrom
|
CA2394980C
(en)
|
1999-12-22 |
2008-05-13 |
Shearwater Corporation |
Sterically hindered derivatives of water soluble polymers
|
EP1259563B2
(en)
|
1999-12-22 |
2016-08-10 |
Nektar Therapeutics |
Method for the preparation of 1-benzotriazolyl carbonate esters of water soluble polymers.
|
US6413507B1
(en)
|
1999-12-23 |
2002-07-02 |
Shearwater Corporation |
Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
|
US6646110B2
(en)
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
ME00415B
(en)
|
2000-02-15 |
2011-10-10 |
Pharmacia & Upjohn Co Llc |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
AU2001238595A1
(en)
|
2000-02-22 |
2001-09-03 |
Shearwater Corporation |
N-maleimidyl polymer derivatives
|
AU2001239857B9
(en)
|
2000-02-25 |
2006-07-27 |
Duke University |
Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
|
AU2001257577A1
(en)
|
2000-02-28 |
2001-09-03 |
Shearwater Corporation |
Water-soluble polymer conjugates of artelinic acid
|
KR100480985B1
(en)
|
2000-05-19 |
2005-04-07 |
이수화학 주식회사 |
Humanized antibodies to the epidermal growth factor receptor
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
US20030119056A1
(en)
|
2000-12-18 |
2003-06-26 |
Ladner Robert Charles |
Focused libraries of genetic packages
|
TW593427B
(en)
|
2000-12-18 |
2004-06-21 |
Nektar Therapeutics Al Corp |
Synthesis of high molecular weight non-peptidic polymer derivatives
|
TWI246524B
(en)
|
2001-01-19 |
2006-01-01 |
Shearwater Corp |
Multi-arm block copolymers as drug delivery vehicles
|
AU2002303431C1
(en)
|
2001-04-19 |
2008-03-06 |
The Regents Of The University Of California |
Methods and composition for the production of orthoganal tRNA-aminoacyltRNA synthetase pairs
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
CN1966525A
(en)
|
2001-06-13 |
2007-05-23 |
根马布股份公司 |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
MXPA04004336A
(en)
|
2001-11-07 |
2005-05-16 |
Nektar Therapeutics Al Corp |
Branched polymers and their conjugates.
|
WO2003039486A2
(en)
|
2001-11-09 |
2003-05-15 |
Idec Pharmaceuticals Corporation |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
DE10156482A1
(en)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispecific antibody molecule
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
US20040110226A1
(en)
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
US7659241B2
(en)
|
2002-07-31 |
2010-02-09 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
AU2003259912B2
(en)
|
2002-08-19 |
2008-10-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Improved methods of in vitro protein synthesis
|
US20040202666A1
(en)
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
BR122018071808B8
(en)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugate
|
US7968684B2
(en)
|
2003-11-12 |
2011-06-28 |
Abbott Laboratories |
IL-18 binding proteins
|
WO2005047334A1
(en)
|
2003-11-13 |
2005-05-26 |
Hanmi Pharmaceutical. Co., Ltd. |
Igg fc fragment for a drug carrier and method for the preparation thereof
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
EP2360186B1
(en)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Anti-P-selectin antibodies
|
WO2005111082A1
(en)
|
2004-04-30 |
2005-11-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-tfr antibody.
|
KR101699142B1
(en)
|
2004-06-18 |
2017-01-23 |
암브룩스, 인코포레이티드 |
Novel antigen-binding polypeptides and their uses
|
KR20120068807A
(en)
|
2004-07-22 |
2012-06-27 |
제넨테크, 인크. |
Her2 antibody composition
|
WO2006031994A2
(en)
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
TWI380996B
(en)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
CN101048506B
(en)
|
2004-10-27 |
2013-06-26 |
斯克利普斯研究院 |
Orthogonal translation components for the in vivo incorporation of unnatural amino acids
|
SG158148A1
(en)
|
2004-12-22 |
2010-01-29 |
Ambrx Inc |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
KR100754667B1
(en)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
|
US8008443B2
(en)
|
2005-04-26 |
2011-08-30 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
WO2008020827A2
(en)
*
|
2005-08-01 |
2008-02-21 |
Biogen Idec Ma Inc. |
Altered polypeptides, immunoconjugates thereof, and methods related thereto
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
CA2624189A1
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2882445A1
(en)
|
2005-12-14 |
2007-06-21 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
CN101384711A
(en)
|
2006-01-19 |
2009-03-11 |
Ambrx公司 |
Non-natural amino acid polypeptides having modulated immunogenicity
|
CN101426817B
(en)
|
2006-04-21 |
2013-07-10 |
诺华有限公司 |
Antagonist anti-cd40 antibody pharmaceutical compositions
|
EP2444499A3
(en)
|
2006-05-02 |
2012-05-09 |
Allozyne, Inc. |
Amino acid substituted molecules
|
DK2035554T3
(en)
|
2006-06-29 |
2013-06-17 |
Univ Leland Stanford Junior |
Cell-free synthesis of proteins containing non-natural amino acids
|
KR20090060294A
(en)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
Modified human plasma polypeptide or fc scaffolds and their uses
|
CN101528914B
(en)
|
2006-09-08 |
2014-12-03 |
Ambrx公司 |
Site specific incorporation of non-natural amino acids by vertebrate cells
|
CA2671851A1
(en)
|
2006-12-28 |
2008-07-10 |
Ambrx, Inc. |
Phenazine and quinoxaline substituted amino acids and polypeptides
|
JP2010526091A
(en)
|
2007-04-30 |
2010-07-29 |
インテザイン テクノロジーズ, インコーポレイテッド |
Modification of biological target groups for the treatment of cancer
|
BRPI0816785A2
(en)
|
2007-09-14 |
2017-05-02 |
Adimab Inc |
rationally designed synthetic antibody libraries, and uses thereof
|
KR101622412B1
(en)
|
2007-10-19 |
2016-05-18 |
제넨테크, 인크. |
Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
|
BRPI0907046A2
(en)
*
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Engineered cysteine antibody, isolated nucleic acid, vector, host cell, antibody conjugate, pharmaceutical composition, methods of detecting cancer, autoimmune, inflammatory or infectious disorders in an individual and inhibiting proliferation of a target cell
|
WO2010051056A2
(en)
*
|
2008-03-11 |
2010-05-06 |
Ambrx, Inc. |
ANTI-FcεRI POLYPEPTIDES AND THEIR USES
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
US20100184134A1
(en)
|
2009-01-12 |
2010-07-22 |
Sutro Biopharma, Inc. |
Dual charging system for selectively introducing non-native amino acids into proteins using an in vitro synthesis method
|
BRPI1006998A2
(en)
|
2009-01-23 |
2015-08-25 |
Biogen Idec Inc |
Stabilized fc polypeptides with reduced effector function and methods of use
|
GB2470770A
(en)
|
2009-06-04 |
2010-12-08 |
Medical Res Council |
Incorporation of unnatural amino acids having an orthogonal functional group into polypeptides using orthogonal tRNA/tRNA synthetase pairs
|
EP2640745B1
(en)
|
2010-09-10 |
2018-11-07 |
MedImmune Limited |
Bivalent and bispecific anti-il6/anti-il23 antibodies
|
SG10201601792UA
(en)
|
2010-12-08 |
2016-04-28 |
Stemcentrx Inc |
Novel modulators and methods of use
|
RU2636029C2
(en)
|
2011-02-01 |
2017-11-17 |
Генмаб А/С |
Human antibodies and conjugates of antibody-preparation against cd74
|
WO2013068874A1
(en)
*
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
JP2015502397A
(en)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
Engineered antibody constant regions for site-specific conjugation, and methods and uses therefor
|
CN102627615B
(en)
|
2012-03-23 |
2014-01-01 |
兰州大学 |
Novel compound L-4-terazine-phenylalanine, preparation method and application thereof
|
DK2859017T3
(en)
|
2012-06-08 |
2019-05-13 |
Sutro Biopharma Inc |
ANTIBODIES INCLUDING PLACE-SPECIFIC NON-NATURAL AMINO ACID, PROCEDURE FOR MANUFACTURING ITS AND METHODS OF USE THEREOF
|
US9732161B2
(en)
|
2012-06-26 |
2017-08-15 |
Sutro Biopharma, Inc. |
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
ES2728864T3
(en)
|
2012-08-31 |
2019-10-29 |
Sutro Biopharma Inc |
Modified amino acids comprising an azido group
|
KR102155389B1
(en)
|
2012-09-24 |
2020-09-11 |
메디뮨 리미티드 |
Cell lines
|
US9902705B2
(en)
|
2012-10-24 |
2018-02-27 |
The General Hospital Corporation |
Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
|
DK3521312T3
(en)
|
2013-02-20 |
2021-06-28 |
Innate Pharma |
COMPOUND BINDING SPECIFICALLY TO KIR3DL2, FOR USE IN THE TREATMENT OF PERIFF T-CELL LYMPHOM
|
ES2658039T3
(en)
|
2013-07-10 |
2018-03-08 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
|
US10975150B2
(en)
|
2014-07-22 |
2021-04-13 |
Sutro Biopharma, Inc. |
Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using anti-CD74 antibodies
|
ME03806B
(en)
|
2014-11-21 |
2021-04-20 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
US10844090B2
(en)
|
2015-01-30 |
2020-11-24 |
Sutro Biopharma, Inc. |
Hemiasterlin derivatives for conjugation and therapy
|
CN106146663B
(en)
|
2015-04-10 |
2019-11-08 |
北京大学 |
Novel antibodies-drug conjugates of unnatural amino acid label and its preparation
|
WO2017132617A1
(en)
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
TW201801751A
(en)
|
2016-05-13 |
2018-01-16 |
塔維達治療公司 |
Targeted constructs and formulations thereof
|
WO2018187074A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|